Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Patient Preference for Early Onset of Efficacy in Migraine Prevention
Headache
Headache Posters (7:00 AM-5:00 PM)
127
Eptinezumab (anti-calcitonin gene-related peptide monoclonal antibody) was associated with an absolute therapeutic benefit of reducing migraine-likelihood on Day-1 post-infusion by 14% and 8% compared with placebo in patients with chronic migraine (CM; PROMISE-2 study) and episodic migraine (EM; PROMISE-1 study), respectively.
To determine the extent that patients with migraine value the early onset of efficacy of preventive migraine treatments.
Adults (≥18yr) with CM or EM self-reporting ≥4 monthly migraine days (MMDs) for ≥3 months, with migraine history for ≥12 months, completed a thresholding exercise (comparing 2 hypothetical treatments by varying 2 key attributes) to ascertain the relative value of migraine prevention on Day-1 post-dosing compared with meaningful reductions in MMDs in the first month post-dosing. Two frames were presented: (1) fixed first-month MMD reduction and varied migraine likelihood on Day-1 post-dosing; (2) fixed migraine likelihood on Day-1 post-dosing and varied first-month MMD reduction.
101 participants (mean age, 50.6yr; 80% female) were included. In participants with CM (n=55), 58.0% considered a 14% migraine-likelihood reduction on Day-1 post-dosing to be at least as important as a reduction of 2 MMDs, and 74.0% indicated that an ≥2-MMD reduction (mean, 5.0) had an equivalent value to a 14% migraine-likelihood reduction on Day-1 post-dosing. In participants with EM (n=35), 51.4% considered an 8% migraine-likelihood reduction on Day-1 post-dosing to be at least as important as a reduction of 1 MMD, and 68.6% indicated that an ≥1-MMD reduction (mean, 2.7) had an equivalent value to an 8% migraine-likelihood reduction on Day-1 post-dosing.
Most patients considered the early onset of migraine-preventive efficacy to be meaningful. Regardless of choice frame, the magnitude of reduction of migraine-likelihood offered by eptinezumab on Day-1 post-infusion was at least as important to patients as clinically relevant reductions in MMDs in the first month after treatment.
Authors/Disclosures
Paul Winner, DO, FAAN (Palm Beach Headache Ctr)
PRESENTER
Dr. Winner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva. Dr. Winner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan. Dr. Winner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck . Dr. Winner has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amgen. Dr. Winner has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Allergan. Dr. Winner has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Lundbeck. Dr. Winner has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Teva. Dr. Winner has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for lilly. The institution of Dr. Winner has received research support from Amgen. The institution of Dr. Winner has received research support from Allergan. The institution of Dr. Winner has received research support from Lundbeck . The institution of Dr. Winner has received research support from Novartis. The institution of Dr. Winner has received research support from Lilly. The institution of Dr. Winner has received research support from Teva. The institution of Dr. Winner has received research support from Supernus. The institution of Dr. Winner has received research support from Biogen. The institution of Dr. Winner has received research support from Avinar. The institution of Dr. Winner has received research support from SAMUS.
Agathe Le Lay (Lundbeck) Agathe Le Lay has received personal compensation for serving as an employee of Lundbeck.
Ann Hartry (Lundbeck) Ann Hartry has received personal compensation for serving as an employee of Lundbeck, LLC.
Thomas Brevig Thomas Brevig has received personal compensation for serving as an employee of H. Lundbeck A/S. Thomas Brevig has received personal compensation for serving as an employee of Gedeon Richter Plc.. Thomas Brevig has stock in H. Lundbeck A/S.
Martin Bog (H Lundbeck A/S) Martin Bøg has received personal compensation for serving as an employee of H Lundbeck A/S.
Anders Lassen (Lundbeck) Anders Lassen has received personal compensation for serving as an employee of Lundbeck. Anders Lassen has received stock or an ownership interest from Lundbeck.
Kevin Marsh Kevin Marsh has received personal compensation for serving as an employee of Evidera. The institution of Kevin Marsh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. The institution of Kevin Marsh has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for CEPI. Kevin Marsh has received stock or an ownership interest from PPD.
Katelyn Cutts (Evidera) Katelyn Cutts has nothing to disclose.
Jessica Ailani, MD, FAAN (Medstar Georgetown Neurology) Dr. Ailani has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Allergan/Abbvie. Dr. Ailani has received personal compensation in the range of $0-$499 for serving as a Consultant for Amgen. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Eli Lilly. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GlaxoSmithKline. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Ailani has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Gore. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ipsen. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merz. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Theranica. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurolief. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Scilex. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Dr. Reddy. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eneura. Dr. Ailani has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Aeon. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Linpharma. Dr. Ailani has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Aeon. Dr. Ailani has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Pain and Headache Report. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Medscape. The institution of Dr. Ailani has received research support from Satsuma. The institution of Dr. Ailani has received research support from Ipsen. The institution of Dr. Ailani has received research support from Parema. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Medical Advisor with SELF.